Enstamont L Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, reducing inflammation, bronchoconstriction, and mucus production associated with allergic responses. The synergistic action of these agents provides comprehensive relief from both immediate and late-phase allergic symptoms. Enstamont L is typically administered once daily, preferably in the evening, to optimize symptom control. It is well-tolerated, with a low incidence of adverse effects; however, patients should be monitored for potential side effects such as headache, fatigue, or gastrointestinal discomfort. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Enstamont L should be used under medical supervision, particularly in pediatric and elderly populations. This combination therapy offers an effective approach for patients inadequately controlled by monotherapy, improving quality of life by mitigating allergic manifestations.